title: Early results from a phase I study on orally administered tris(8-quinolinolato)gallium(III) (FFC11, KP46) in patients with solid tumors--a CESAR study (Central European Society for Anticancer Drug Research--EWIV).
authors.affiliation: Onkologisches Zentrum, III. Medizinische Klinik, Fakultät für Klinische Medizin Mannheim der Universität Heidelberg, Germany. ralf.hofheinz@med3.ma.uni-heidelberg.de
authors.forename: R D
authors.initials: RD
authors.lastname: Hofheinz
authors.forename: C
authors.initials: C
authors.lastname: Dittrich
authors.forename: M A
authors.initials: MA
authors.lastname: Jakupec
authors.forename: A
authors.initials: A
authors.lastname: Drescher
authors.forename: U
authors.initials: U
authors.lastname: Jaehde
authors.forename: M
authors.initials: M
authors.lastname: Gneist
authors.forename: N
authors.initials: N
authors.lastname: Graf von Keyserlingk
authors.forename: B K
authors.initials: BK
authors.lastname: Keppler
authors.forename: A
authors.initials: A
authors.lastname: Hochhaus
mesh_terms: D000284:Administration, Oral; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000493:pharmacokinetics*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008297:Male; D020714:Maximum Tolerated Dose; D009369:Neoplasms / Q000378:metabolism*; D009942:Organometallic Compounds / Q000009:adverse effects / Q000493:pharmacokinetics*; D015125:Oxyquinoline / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D012958:Societies, Scientific
chemical_list: D000970:Antineoplastic Agents; D009942:Organometallic Compounds; C408502:tris(8-quinolinolato)gallium (III); D015125:Oxyquinoline